Vertex Q1 revenue slightly below forecasts as key drug sales miss estimates, but Alyftrek revenue surges

Vertex Pharmaceuticals reported first‑quarter revenue of about $3 billion, falling just short of Wall Street expectations. The modest miss left the stock largely unchanged on the day of the release.

The bulk of the revenue still came from Trikafta, the three‑in‑one cystic fibrosis therapy, which generated $2.35 billion but was down 7% compared with the same quarter a year earlier.

Alyftrek, a newer successor drug, saw its sales jump eightfold to $424 million, a growth the company suggested could signal a healthy switch rate among patients.

Sales of the gene‑editing therapy Casgevy and the non‑opioid pain drug Journavx each fell short of analyst forecasts by double‑digit percentages, though Vertex highlighted that both product launches are progressing.

Overall, investor reaction was muted, with shares barely moving after the earnings announcement.